Clinical Trial Update: GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of GSK1120212 (trametinib) in surgically resectable oral cavity squamous cell carcinoma completed, with results posted December 26, 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Cavity Squamous Cell Carcinoma

Drugs mentioned

• GSK1120212 (trametinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Neoplasms, Oral, Mouth Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2016-12-26